Sarah Goldberg, MD, MPH

A phase 1/1b first-in-human study is evaluating the CNS-penetrant selective ERBB2 inhibitor CGT4255 across multiple tumor types, including HER2-positive breast cancer with brain metastases.

Clinicians share practical tips to prevent amivantamab–lazertinib rash, streamline orders, manage edema, and use short-term DOAC prophylaxis.

Learn how proactive prophylaxis makes subcutaneous amivantamab plus lazertinib more tolerable, cutting severe rash, nail issues and clot risk.

Learn how monthly subcutaneous amivantamab cuts clinic time, eases infusion capacity, and supports dose tweaks without sacrificing outcomes.

Monthly subcutaneous amivantamab plus lazertinib shows strong first-line EGFR NSCLC responses, fewer visits, and far fewer reactions.

Learn how clinicians choose first-line EGFR lung cancer therapy, weigh brain mets risk, and manage combo side effects for lasting benefit.

New data show amivantamab+lazertinib boosts survival vs osimertinib in EGFR lung cancer, with Q4W subcutaneous dosing and side-effect tips.

New data show amivantamab plus lazertinib boosts survival and brain control in EGFR+ lung cancer, with convenient Q4W injection tips.